Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report)'s stock had its "buy" rating reaffirmed by Needham & Company LLC in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $7.00 price objective on the stock. Needham & Company LLC's target price points to a potential upside of 171.32% from the stock's current price.

TSHA has been the subject of several other reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday. JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Piper Sandler initiated coverage on shares of Taysha Gene Therapies in a research report on Tuesday, April 9th. They set an "overweight" rating and a $9.00 price target on the stock. Chardan Capital raised their target price on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Thursday, March 21st. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies presently has a consensus rating of "Buy" and a consensus target price of $6.88.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA traded up $0.16 during trading on Thursday, hitting $2.58. 1,491,328 shares of the stock were exchanged, compared to its average volume of 2,519,824. The company has a fifty day moving average price of $2.65 and a two-hundred day moving average price of $2.09. The company has a market cap of $482.51 million, a PE ratio of -3.85 and a beta of 0.37. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.54. Taysha Gene Therapies has a 12-month low of $0.50 and a 12-month high of $3.89.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The company had revenue of $3.60 million during the quarter, compared to analysts' expectations of $4.75 million. On average, analysts forecast that Taysha Gene Therapies will post -0.39 EPS for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds have recently bought and sold shares of TSHA. China Universal Asset Management Co. Ltd. raised its holdings in shares of Taysha Gene Therapies by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company's stock worth $103,000 after acquiring an additional 14,286 shares during the period. Cannon Global Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies during the first quarter worth $69,000. Chicago Partners Investment Group LLC raised its holdings in shares of Taysha Gene Therapies by 21.4% during the fourth quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company's stock worth $239,000 after acquiring an additional 23,740 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth $370,000. Finally, Avoro Capital Advisors LLC raised its holdings in shares of Taysha Gene Therapies by 11.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company's stock worth $7,709,000 after acquiring an additional 430,555 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.